MOG and multiple sclerosis: The findings of a lack of effect of systemically administered XPro1595 were unanticipated as we and others have previously demonstrated that systemic administration of XPro1595 significantly improved clinical scores, reduced axonal damage, and promoted remyelination in myelin oligodendrocyte glycoprotein-induced experimental EAE, a mouse model of multiple sclerosis [9,20].